Company Insights

MLSS customer relationships

Explore interactive graphBrowse insights index
MLSS customer relationship map

MLSS customer relationships: what the public record tells investors about revenue sources and concentration

Milestone Scientific (MLSS) sells precision anesthesia systems—most notably the STA Single Tooth Anesthesia (STA) for dentistry and the CompuFlo® Epidural System for pain management—through a mix of direct e‑commerce, distributor channels and institutional contracts, monetizing primarily via device sales and consumable follow‑on revenue. E‑commerce is already the dominant revenue channel, while distributor partnerships and a newly approved Federal Supply Schedule broaden institutional access, creating a two‑pronged commercial model that balances many small, direct buyers with strategic institutional placements. For investors tracking customer risk and revenue durability, the mix implies high channel concentration on e‑commerce with low single‑customer concentration but growing institutional opportunity.
Learn more about coverage and signals at https://nullexposure.com/.

Quick takeaways for an investment view

  • E‑commerce accounted for 60% of MLSS net product sales in FY2024, up from 48% in FY2023—this is the firm’s primary route to market.
  • MLSS has secured a Federal Supply Schedule (GSA) approval, establishing a formal contracting posture for U.S. government procurement.
  • Customer tickets are generally small, with documented single‑buyer purchases in the low‑tens of thousands and limited exposure to any single offshore channel in 2024.
    These elements point to a commercial model with strong channel control but concentrated execution risk around online sales and distributor management.

How the company’s contracting posture and commercial maturity present risk and opportunity

MLSS operates with a mixed contracting posture. The company sells directly to dental offices via an e‑commerce portal, creating many low‑dollar, transactional relationships that drive volume and margin control through direct channels. Simultaneously, MLSS uses exclusive and non‑exclusive distributors to reach global markets, and the GSA approval positions the company to win institutional contracts with predictable procurement processes.

  • Concentration and scale: high dependency on online sales implies operational concentration in digital order fulfillment and customer acquisition, even as individual customer dollar exposure is low.
  • Criticality and stickiness: medical device placements such as CompuFlo at pain centers provide higher stickiness than one‑off dental purchases, increasing the strategic value of clinical accounts.
  • Maturity: GSA schedule approval and the rollout of CompuFlo into clinical sites indicate a commercialization phase beyond early pilot activity.

These are company‑level signals derived from public filing excerpts and product launch reports; where a constraint explicitly names a customer, that is acknowledged below.

Customer relationships in the public record

STEMMEE — a board‑linked pain clinic with a small, documented purchase

The University Pain Medicine Center (STEMMEE), whose CEO is a Milestone board member (Dr. D. Demesmin), agreed to purchase MLSS products under the same terms as other U.S. medical pain clinics and recorded approximately $21,000 in purchases for the year ended December 31, 2024. This is a small, traceable clinical customer with a governance linkage disclosed in the FY2024 10‑K.

Source: MLSS FY2024 10‑K filing (disclosure of purchases by University Pain Medicine Center/STEMMEE; purchases reported for 2024).

The Painless Center — commercial deployment of CompuFlo in a regional pain clinic

MLSS commenced sales of the CompuFlo® Epidural System to The Painless Center in Tenafly, New Jersey, marking a commercial placement of the epidural product in a clinical setting. The rollout was reported in a MarketScreener news item covering operational progress under new leadership, dated July 17, 2025.

Source: MarketScreener coverage of Milestone Scientific sales commencement at The Painless Center (July 17, 2025).

Implications for revenue predictability and customer concentration

  • Low single‑customer revenue risk but high channel dependency. The documented $21,000 transaction size for STEMMEE and broader reporting of small, frequent sales are consistent with a business that derives revenue from many low‑dollar buyers; this reduces headline concentration risk but increases sensitivity to customer acquisition costs and platform performance. The FY2024 e‑commerce share (60% of net product sales) confirms material reliance on direct online sales.
  • Institutional upside is real and trackable. GSA/FSS approval provides a formal route into government procurement and larger institutional buyers, which can improve revenue visibility and margin profile when translated into sustained orders. The clinical placement at The Painless Center demonstrates incremental success commercializing CompuFlo beyond pilot stages.
  • Distribution breadth reduces geographic delivery risk but raises execution complexity. MLSS sells in the U.S., Canada and over 41 other countries, leveraging both exclusive and non‑exclusive distributors; global reach tempers market concentration yet creates operational dependencies on channel partners.

If you want a concise, investment‑grade view of MLSS customer signals and channel exposures, visit https://nullexposure.com/ for modeled relationship analysis.

What investors should monitor next

  • E‑commerce retention and customer acquisition economics. With 60% of net product sales coming from the company portal in FY2024, any shift in online traffic, conversion or logistic costs will directly affect margins. The company’s ability to scale repeat consumable sales through that channel determines long‑term unit economics.
  • Conversion of GSA access into recurring institutional orders. Winning on the Federal Supply Schedule requires successful contracting and supply performance; institutional volumes would materially change revenue stability and average order size.
  • Distributor performance and international sales cadence. The company’s use of exclusive/non‑exclusive distributors across 41+ countries is a growth lever and an operational risk—tracking distributor inventory, training, and regional uptake is essential.

For deeper relationship profiling and ongoing monitoring of MLSS clients and channel signals, explore our coverage at https://nullexposure.com/.

Final assessment

Milestone Scientific’s commercial position blends highly scalable direct e‑commerce sales with strategic institutional placements and a global distributor network. The public record shows mostly small clinical and dental purchases with early but tangible traction for CompuFlo in pain clinics and formal government procurement access via the GSA schedule. For investors, the core question is execution: can MLSS convert government and clinical footholds into larger, recurring orders while maintaining efficiency in its predominant e‑commerce channel? Monitoring e‑commerce metrics, distributor fulfillment, and institutional contract wins provides a clear roadmap to evaluate revenue durability and upside.